

Strategic analysis of the European vaccines market for infectious diseases - understanding the quantitative aspects and leveraging growth opportunities for vaccines manufacturers

Aiswariya Chidambaram
Frost & Sullivan, India

This research service aims to assess and analyze the European vaccines market, particularly the key five countries of Western Europe namely Germany, the United Kingdom, France, Italy and Spain, map the key trends and dynamics shaping the industry sector, and provide economic revenue forecasts and strategic recommendations for the success of the market participants. The European vaccines market, valued at \$6.36 billion in 2011 is expected to grow at a compound annual growth rate of 9.6 per cent over the next seven years. Market segmentation is done based on demographics which include adult and paediatric vaccines as well the key infectious diseases which include Measles-Mumps-Rubella (MMR), Diphtheria-Tetanus-Pertussis (DTP), influenza, hepatitis, Human Papilloma Virus (HPV) cancer, rotavirus infection, meningococcal and pneumococcal diseases. Although Europe has been enjoying the leadership position in the global vaccines market over a decade in terms of vaccines research, development, and production, a rapid shift in power to the United States and the narrowing of the gap between the two regions is anticipated in the future, owing to the rapid growth, increasing R&D investments and relative competitiveness of the United States. As vaccine manufacturers increasingly leverage the novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialisation stage, several new vaccines for both infectious diseases such as AIDS, dengue fever, tuberculosis, and malaria as well as non-infectious diseases like diabetes, allergies, Alzheimer's disease, cancers, addictions, and public health threats (bio-terrorism) are likely to be available in the future. Next-generation vaccines such as edible plant-based vaccines are also likely to have a significant impact on vaccine development. Research methodology involves extensive secondary research from sources such as Frost & Sullivan's in-house database, company annual reports, scientific journals, private and public organisations such as WHO, EBC, Alzheimer Europe and so on as well primary interviews with industry stake holders such as tier 1 and tier 2 companies, industry associations, healthcare providers and regulatory authorities.

Biography

Aiswariya Chidambaram is a senior research analyst within the healthcare practice of Frost & Sullivan. She has authored several syndicated and customised market research reports on key therapeutic and service areas for both the European and Global pharmaceutical and biotechnology markets. Besides she has contributed articles, briefings and interviews to widely read publications worldwide such as PharmaVoice, European Public Service Review, European Biopharmaceutical Review, to name a few and has also identified and awarded companies demonstrating excellence in specific market segments and technologies in the healthcare industry. Aiswariya has completed her B.Tech in Biotechnology from Anna University.

AiswariyaC@Frost.com